Placebo for MEM 3454
Sponsors
Memory Pharmaceuticals
Conditions
Cognitive Impairment Associated With SchizophreniaSchizophrenia
Phase 2
Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia
NCT00604760
Start: 2007-12-31Target: 160Updated: 2008-12-08
A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia Patients
NCT00725855
Start: 2008-08-31End: 2009-04-30Target: 12Updated: 2008-07-31